Table 2.
Estimate mean differences at baseline, 6 months and 12 months after treatment.
| Estimate | SE | % Change | p value | |
|---|---|---|---|---|
| Fat body mass (g) | ||||
| Baseline vs. 12 months | 2920.7 | 541.6 | 13.8% | <0.001 |
| Lean body mass (g) | ||||
| Baseline vs. 12 months | −187.1 | 660.4 | −0.3% | 0.8 |
| Body mass index (kg/m2) | ||||
| Baseline vs. 6 months | 0.52 | 0.25 | 1.9% | 0.04 |
| Baseline vs. 12 months | 0.73 | 0.25 | 2.7% | 0.005 |
| Total cholesterol (mg/dL) | ||||
| Baseline vs. 6 months | 4.03 | 5.21 | 2.1% | 0.4 |
| Baseline vs. 12 months | −4.03 | 5.21 | −2.1% | 0.4 |
| HDL cholesterol (mg/dL) | ||||
| Baseline vs. 6 months | 2.4 | 1.4 | 4.4% | 0.08 |
| Baseline vs. 12 months | −0.5 | 1.4 | −0.9% | 0.7 |
| LDL cholesterol (mg/dL) | ||||
| Baseline vs. 6 months | −1.34 | 4.53 | −1.2% | 0.7 |
| Baseline vs. 12 months | −2.59 | 4.53 | −2.3% | 0.8 |
| Triglycerides (mg/dL) | ||||
| Baseline vs. 6 months | 21.9 | 11.1 | 19.9% | 0.05 |
| Baseline vs. 12 months | 9.6 | 11.1 | 8.7% | 0.4 |
| Glucose (mg/dL) | ||||
| Baseline vs. 6 months | 3.00 | 2.11 | 2.9% | 0.2 |
| Baseline vs. 12 months | 1.68 | 2.11 | 1.6% | 0.4 |
| HbA1c (mmol/mol) | ||||
| Baseline vs. 6 months | 2.75 | 0.61 | 6.9% | <0.001 |
| Baseline vs. 12 months | 3.55 | 0.61 | 8.9% | <0.001 |
| FSH (UI/L) | ||||
| Baseline vs. 6 months | −10.2 | 1.7 | −87.9% | <0.001 |
| Baseline vs. 12 months | −9.3 | 1.7 | −79.8% | <0.001 |
| PSA (ng/mL) | ||||
| Baseline vs. 6 months | −12.4 | 5.0 | −97.3% | 0.001 |
| Baseline vs. 12 months | −12.5 | 5.0 | −98.5% | 0.001 |
SE standard error, BMI body mass index, HDL high-density lipoprotein, LDL low-density lipoprotein, HbA1c glycated hemoglobin, FSH follicle-stimulating hormone, PSA prostate specific antigen.